S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
"Prepare for Five Years of Famine" (Ad)
NASDAQ:NVAX

Novavax - NVAX Earnings Date, Estimates & Call Transcripts

$41.36
+1.08 (+2.68%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$38.16
$41.93
50-Day Range
$36.28
$76.12
52-Week Range
$34.88
$277.80
Volume
9.60 million shs
Average Volume
8.55 million shs
Market Capitalization
$3.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$151.00

Earnings Summary

Upcoming
Earnings Date
Nov. 3Estimated
Actual EPS
(Aug. 8)
-$6.53 Missed By -$12.04
Consensus EPS
(Aug. 8)
$5.51
Last Year's Q3 EPS
(8/5/2021)
-$4.75
Skip Charts & View Estimated and Actual Earnings Data

NVAX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NVAX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Novavax Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20222$2.04$3.67$2.86 
Q2 20222$4.62$6.70$5.66 
Q3 20222$0.93$10.74$5.84 
Q4 20222$1.79$16.08$8.94 
FY 20228$9.38$37.19 $23.29

NVAX Earnings Date and Information

Novavax last issued its earnings data on August 8th, 2022. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing analysts' consensus estimates of $5.51 by $12.04. The company had revenue of $186 million for the quarter, compared to the consensus estimate of $1.02 billion. Its quarterly revenue was down 37.6% compared to the same quarter last year. Novavax has generated ($19.46) earnings per share over the last year (($19.46) diluted earnings per share). Earnings for Novavax are expected to decrease by -61.00% in the coming year, from $27.23 to $10.62 per share. Novavax has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based off prior year's report dates.

Novavax Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/3/2022
(Estimated)
        
8/8/2022Q2$5.51($6.53)($12.04)$1.02 billion$186.00 million    
5/9/2022Q1 2022$3.33$2.56($0.77)$2.56$845.20 million$703.97 million    
2/28/2022Q4 2021($1.43)($11.18)($9.75)($11.18)$331.79 million$222.20 million    
11/4/20219/30/2021($4.04)($4.31)($0.27)($4.31)$347.34 million$178.80 million    
8/5/20216/30/2021($3.63)($4.75)($1.12)($4.75)$370.80 million$298.02 million    
5/10/20213/31/2021($2.65)($3.05)($0.40)($3.05)$233.90 million$447.00 million  
3/1/202112/31/2020($1.53)($2.70)($1.17)($2.70)$202.44 million$279.66 million  
11/9/20209/30/2020$2.36($3.21)($5.57)($3.21)$230.56 million$157.00 million  
8/10/20206/30/2020($0.60)($0.30)+$0.30($0.30)$5.67 million$35.50 million  
5/11/20203/31/2020($0.67)($0.58)+$0.09($0.58)$3.50 million$3.38 million  
3/11/202012/31/2019($1.06)($1.13)($0.07)($1.13)$3.99 million$8.82 million  
11/7/2019Q3 19($0.98)($0.74)+$0.24($1.32)$4.40 million$2.51 million  
8/7/2019Q2 2019($1.61)($1.69)($0.08)($1.69)$3.53 million$3.36 million
5/2/20193/31/2019($2.40)($2.20)+$0.20($0.11)$4.80 million$3.98 million  
3/18/201912/31/2018($2.40)($2.60)($0.20)($0.13)$7.87 million$6.13 million  
11/7/20189/30/2018($2.40)($2.40)($0.12)$9.63 million$7.70 million  
8/8/2018Q2 2018($2.40)($2.40)($0.12)$10.02 million$10.80 million
5/9/2018Q1 18($2.60)($2.80)($0.20)($0.14)$9.33 million$9.70 million
3/14/2018Q4 17($3.00)($3.20)($0.20)($0.16)$7.98 million$10.40 million  
11/7/2017Q3 2017($3.20)($3.00)+$0.20($0.15)$6.42 million$8.35 million
8/8/2017Q2 2017($3.20)($3.20)($0.16)$6.15 million$6.70 million  
5/8/2017Q1 2017($3.60)($3.20)+$0.40($0.16)$6.17 million$5.68 million  
2/27/2017Q416($4.60)($4.20)+$0.40($0.21)$5.45 million$5.40 million  
11/9/2016Q316($5.20)($4.80)+$0.40($0.24)$4.02 million$3.20 million  
8/9/2016Q216($5.00)($5.80)($0.80)($0.29)$8.03 million$2.50 million  
5/4/2016Q1($5.40)($5.80)($0.40)($0.29)$10.39 million$4.20 million  
2/29/2016Q415($2.80)($5.80)($3.00)($0.29)$8.07 million$5.90 million  
11/9/2015Q315($1.80)($2.40)($0.60)($0.12)$10.59 million$6.50 million
8/10/2015Q215($1.80)($1.60)+$0.20($0.08)$9.90 million$14.00 million  
5/7/2015Q115($2.20)($2.00)+$0.20($0.10)$9.70 million$9.88 million
2/26/2015Q4 14($1.60)($2.60)($1.00)($0.13)$9.60 million$6.70 million
11/5/2014Q314($1.40)($1.60)($0.20)($0.08)$9.20 million$8.20 million
8/6/2014Q214($1.40)($1.60)($0.20)($0.08)$8.74 million$8.26 million  
5/7/2014Q114($1.40)($1.40)($0.07)$3.80 million$7.50 million
3/10/2014Q4 2013($1.40)($1.40)($0.07)$6.22 million$8.70 million
11/7/2013Q3 2013($1.20)($1.80)($0.60)($0.09)$4.56 million$4.80 million
8/8/2013Q2 2013($1.00)($1.60)($0.60)($0.08)$4.45 million$3.50 million
5/7/2013Q1 2013($0.80)($1.40)($0.60)($0.07)$5.54 million$3.80 million
3/1/2013Q4 2012($0.80)($1.20)($0.40)$5.85 million$4.57 million  
11/2/2012Q312($1.00)($1.00)$7.59 million$5.80 million
8/3/2012($1.40)($1.00)+$0.40
5/4/2012($0.80)($1.20)($0.40)
3/9/2012($0.80)($0.60)+$0.20
11/4/2011($1.20)($0.60)+$0.60  
8/5/2011($1.60)($0.80)+$0.80  
5/9/2011($1.40)($1.40)  
3/28/2011($1.80)($1.20)+$0.60  
11/5/2010Q3 2010($1.80)($2.00)($0.20)($0.10)
8/6/2010Q2 2010($2.00)($1.80)+$0.20($0.09)
5/10/2010Q1 2010($2.60)($2.20)+$0.40($0.11)
3/12/2010Q4 2009($0.80)($3.00)($2.20)($0.15)
11/6/2009Q3 2009($1.80)($1.60)+$0.20($0.08)
8/7/2009Q2 2009($2.20)($2.00)+$0.20($0.10)
5/8/2009Q1 2009($2.40)($2.40)($0.12)
3/31/2009Q4 2008($2.60)($2.20)+$0.40($0.07)
11/10/2008Q3 2008($2.80)($3.20)($0.40)($0.20)
8/8/2008Q2 2008($2.80)($2.80)($0.13)
5/9/2008Q1 2008($2.40)($2.40)($0.11)
3/14/2008Q4 2007($2.60)($2.20)+$0.40($0.07)












Novavax Earnings - Frequently Asked Questions

When is Novavax's earnings date?

Novavax has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based off last year's report dates. Learn more on NVAX's earnings history.

Did Novavax beat their earnings estimates last quarter?

In the previous quarter, Novavax (NASDAQ:NVAX) missed the analysts' consensus estimate of $5.51 by $12.04 with a reported earnings per share (EPS) of ($6.53). Learn more on analysts' earnings estimate vs. NVAX's actual earnings.

How can I listen to Novavax's earnings conference call?

The conference call for Novavax's latest earnings report can be listened to online. Listen to Conference Call

How can I read Novavax's conference call transcript?

The conference call transcript for Novavax's latest earnings report can be read online. Read Transcript

How much revenue does Novavax generate each year?

Novavax (NASDAQ:NVAX) has a recorded annual revenue of $1.15 billion.

How much profit does Novavax generate each year?

Novavax (NASDAQ:NVAX) has a recorded net income of -$1.74 billion. NVAX has generated -$19.46 earnings per share over the last four quarters.

What is Novavax's price-to-earnings ratio?

Novavax (NASDAQ:NVAX) has a forward price-to-earnings ratio of 1.52. The price/earnings-to-growth ratio is 0.04.

What is Novavax's EPS forecast for next year?

Novavax's earnings are expected to decrease from $27.23 per share to $10.62 per share in the next year, which is a -61.00% change.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:NVAX) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.